Mark Beresford

3.3k total citations · 1 hit paper
50 papers, 1.7k citations indexed

About

Mark Beresford is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Cancer Research. According to data from OpenAlex, Mark Beresford has authored 50 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 18 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Cancer Research. Recurrent topics in Mark Beresford's work include Breast Cancer Treatment Studies (15 papers), MRI in cancer diagnosis (9 papers) and Radiomics and Machine Learning in Medical Imaging (6 papers). Mark Beresford is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), MRI in cancer diagnosis (9 papers) and Radiomics and Machine Learning in Medical Imaging (6 papers). Mark Beresford collaborates with scholars based in United Kingdom, United States and Australia. Mark Beresford's co-authors include Andreas Makris, George D. Wilson, Anwar R. Padhani, Richard Benson, Thankamma Ajithkumar, David Gillatt, David J. Collins, N. Jane Taylor, James Stirling and Mei-Lin W. Ah-See and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Radiology.

In The Last Decade

Mark Beresford

47 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

2020 280 citations Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Mark Beresford

Since Specialization

Citations

This map shows the geographic impact of Mark Beresford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Beresford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Beresford more than expected).

Fields of papers citing papers by Mark Beresford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Beresford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Beresford. The network helps show where Mark Beresford may publish in the future.

Co-authorship network of co-authors of Mark Beresford

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Beresford. A scholar is included among the top collaborators of Mark Beresford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Beresford. Mark Beresford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2− advanced breast cancer in Europe 2025 ·Breast Cancer Research and Treatment ·Olga Oikonomidou, Mark Beresford, (unknown), (unknown), Rohan Parikh, (unknown), Connie Chen, Justin Doan, Benjamin Li, (unknown), (unknown), María I. Jiménez, Keith L. Davis, Edward Broughton	0
2	The effects of exercise training for eight weeks on immune cell characteristics among breast cancer survivors 2023 ·Frontiers in Sports and Active Living ·(unknown), (unknown), Mark Beresford, John P. Campbell, Dylan Thompson, James Turner	4
3	‘You’re kind of left to your own devices’: a qualitative focus group study of patients with breast, prostate or blood cancer at a hospital in the South West of England, exploring their engagement with exercise and physical activity during cancer treatment and in the months following standard care 2022 ·BMJ Open ·Sian K. Smith, Gareth Wiltshire, (unknown), Haryana M. Dhillon, Mike Osborn, Sarah Wexler, Mark Beresford, Mark Tooley, James Turner	8
4	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial breakdown → 2020 ·The Lancet Oncology ·Leisha A. Emens, Francisco J. Esteva, Mark Beresford, Cristina Saura, Michelino De Laurentiis, Sung‐Bae Kim, Seock‐Ah Im, Yifan Wang, Roberto Salgado, Aruna Mani, Jigna Shah, Chiara Lambertini, Haiying Liu, Sanne Lysbet de Haas, Monika Patre, Sherene Loi	280
5	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer 2017 ·Journal of Clinical Oncology ·Thomas Powles, Robert Huddart, Tony Elliott, (unknown), Charlotte Ackerman, Robert J. Jones, Syed A. Hussain, Simon J. Crabb, Satinder Jagdev, John Chester, Serena Hilman, Mark Beresford, Graham Macdonald, Santhanam Sundar, J. Frew, Andrew Stockdale, Simon Hughes, Daniel M. Berney, Simon Chowdhury	142
6	Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice 2017 ·Clinical Oncology ·Henry Cain, Iain R. Macpherson, Mark Beresford, Sarah E. Pinder, (unknown), J. Michael Dixon	87
7	Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer 2016 ·Targeted Oncology ·Hartmut Kristeleit, Marina Parton, Mark Beresford, Iain R. Macpherson, Rajan Sharma, (unknown), Muireann Kelleher	6
8	Arterial input functions in dynamic contrast-enhanced magnetic resonance imaging: which model performs best when assessing breast cancer response? 2016 ·British Journal of Radiology ·David Woolf, N. Jane Taylor, Andreas Makris, Nina Tunariu, David J. Collins, Sonia P. Li, Mei-Lin W. Ah-See, Mark Beresford, Anwar R. Padhani	13
9	Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer 2015 ·Oncotarget ·Carlo Palmieri, Iain R. Macpherson, (unknown), Felipe Ades, Pippa Riddle, (unknown), (unknown), Bárbara Stanley, Deep Shah, Ondřej Gojiš, Adam Januszewski, C. Lewanski, Rebecca Asher, Daniel Lythgoe, Evandro de Azambuja, Mark Beresford, Sacha J. Howell	4
10	Assessing response in breast cancer with dynamic contrast-enhanced magnetic resonance imaging: Are signal intensity–time curves adequate? 2014 ·Breast Cancer Research and Treatment ·David Woolf, Anwar R. Padhani, N. Jane Taylor, Andrew Gogbashian, Sonia P. Li, Mark Beresford, Mei-Lin Ah-See, James Stirling, David J. Collins, Andreas Makris	24
11	Use of Dynamic Contrast-enhanced MR Imaging to Predict Survival in Patients with Primary Breast Cancer Undergoing Neoadjuvant Chemotherapy 2011 ·Radiology ·Sonia P. Li, Andreas Makris, Mark Beresford, N. Jane Taylor, Mei-Lin W. Ah-See, James Stirling, James A. d’Arcy, David J. Collins, Robert Kozarski, Anwar R. Padhani	86
12	Vascular characterisation of triple negative breast carcinomas using dynamic MRI 2011 ·European Radiology ·Sonia P. Li, Anwar R. Padhani, N. Jane Taylor, Mark Beresford, Mei-Lin W. Ah-See, James Stirling, James A. d’Arcy, David J. Collins, Andreas Makris	69
13	A Qualitative Systematic Review of the Evidence Base for Non-cross-resistance between Steroidal and Non-steroidal Aromatase Inhibitors in Metastatic Breast Cancer 2010 ·Clinical Oncology ·Mark Beresford, Indra Tumur, J. Chakrabarti, Julian A. Barden, Nanyan Rao, Andreas Makris	21
14	Primary Human Breast Adenocarcinoma: Imaging and Histologic Correlates of Intrinsic Susceptibility-weighted MR Imaging before and during Chemotherapy 2010 ·Radiology ·Sonia P. Li, N. Jane Taylor, Andreas Makris, Mei-Lin W. Ah-See, Mark Beresford, James Stirling, James A. d’Arcy, David J. Collins, Anwar R. Padhani	45
15	A Systematic Review of the Role of Imaging before Salvage Radiotherapy for Post-prostatectomy Biochemical Recurrence 2009 ·Clinical Oncology ·Mark Beresford, David Gillatt, Richard Benson, Thankamma Ajithkumar	121
16	Assessment of clinical response after two cycles of primary chemotherapy in breast cancer 2007 ·Breast Cancer Research and Treatment ·Mark Beresford, David J. Stott, Andreas Makris	14
17	Measuring proliferation in breast cancer: practicalities and applications 2006 ·Breast Cancer Research ·Mark Beresford, George D. Wilson, Andreas Makris	155
18	Neoadjuvant endocrine therapy in breast cancer 2006 ·Cancer Treatment Reviews ·Mark Beresford, D. Ravichandran, Andreas Makris	8
19	The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer 2006 ·British Journal of Cancer ·Mark Beresford, Adrian L. Harris, (unknown), Frances Daley, Anwar R. Padhani, Andreas Makris	42
20	Imaging breast cancer response during neoadjuvant systemic therapy 2005 ·Expert Review of Anticancer Therapy ·Mark Beresford, Anwar R. Padhani, Vicky Goh, Andreas Makris	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact